• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

    6/1/22 9:35:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care
    Get the next $IRMD alert in real time by email

    Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately.

    Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously, Chris played a key role as Chief Financial and Operating Officer at a NASDAQ-listed medical device company, where he led them through an IPO process and subsequent scale-up during a period when their market cap grew from approximately $10 million pre-IPO to $600 million. Chris joins us at time when we have a strong balance sheet and see exciting milestones ahead, including the continued commercial launch of our flagship S-Series OCT and the ongoing development of our next-gen AI technology now being evaluated in a pivotal trial."

    Chris Scott, Perimeter's Chief Financial Officer stated, "I am excited to join Perimeter and their efforts to bring Perimeter's transformative ultra-high resolution medical imaging technology to market with the aim of improving patient outcomes and reducing healthcare costs. Perimeter has many opportunities for growth, and I look forward to contributing to the advancement of this game-changing technology."

    Mr. Scott brings to Perimeter his extensive experience in finance and accounting, as well as operations at a public company within the medtech sector. Prior to joining Perimeter, Mr. Scott served as Chief Financial and Operating Officer at iRadimed Corporation (NASDAQ:IRMD) since December 2013. Previously, Mr. Scott held a management position at Darden Restaurants, Inc. from 2010 to 2013, where he provided accounting and reporting oversight. From 2002 to 2010, Mr. Scott served as an auditor and senior manager at KPMG LLP. Mr. Scott received a B.S. in Accounting from the University of Central Florida in 2002.

    In connection with the appointment of Mr. Scott as Chief Financial Officer, the Company has issued to Mr. Scott 350,000 stock options pursuant to the Company's existing stock option plan and subject to TSX Venture Exchange ("TSXV") acceptance. Each stock option is exercisable to purchase one common share of the Company at $1.92 (being the closing price of the Company's common shares on the TSXV on May 31, 2022) for a period of ten years from the grant date.

    About Perimeter Medical Imaging AI, Inc.

    Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSXV:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation, artificial intelligence technology that is currently under clinical development. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Forward-Looking Statements

    This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist; Perimeter's expected development activities and the expected details regarding Perimeter's ongoing clinical trials are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2021, which is available on Perimeter's SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005888/en/

    Get the next $IRMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRMD

    DatePrice TargetRatingAnalyst
    4/12/2023$50.00Buy
    Lake Street
    More analyst ratings

    $IRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Allen Monty K sold $76,148 worth of shares (1,102 units at $69.10), decreasing direct ownership by 5% to 19,898 units (SEC Form 4)

    4 - IRADIMED CORP (0001325618) (Issuer)

    8/6/25 8:00:05 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    CHIEF FINANCIAL OFFICER Glenn John converted options into 5,796 shares and covered exercise/tax liability with 1,412 shares, increasing direct ownership by 50% to 13,151 units (SEC Form 4)

    4 - IRADIMED CORP (0001325618) (Issuer)

    6/23/25 8:00:21 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by CHIEF FINANCIAL OFFICER Glenn John

    4/A - IRADIMED CORP (0001325618) (Issuer)

    4/7/25 4:10:04 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    SEC Filings

    View All

    SEC Form 144 filed by iRadimed Corporation

    144 - IRADIMED CORP (0001325618) (Subject)

    8/6/25 12:20:05 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by iRadimed Corporation

    10-Q - IRADIMED CORP (0001325618) (Filer)

    8/1/25 4:06:06 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IRADIMED CORP (0001325618) (Filer)

    8/1/25 8:32:35 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results

    Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per share of common stock for the third quarter of 2025, payable on August 28, 2025. ORLANDO, Fla., Aug. 01, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ

    8/1/25 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

    ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI52cf21ec526142b8b6142d07c87cfcf9. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available re

    7/25/25 4:05:00 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System

    WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ:IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005. The MRidium® 3870 is poised to strengthen Iradimed's leadership for MRI-compatible infusion, addressing growing demands for safe and reliable fluid delivery in diagnostic imagi

    5/29/25 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on iRadimed with a new price target

    Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00

    4/12/23 9:17:10 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Leadership Updates

    Live Leadership Updates

    View All

    IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

    WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,

    10/6/22 4:05:00 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

    Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously

    6/1/22 9:35:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Financials

    Live finance-specific insights

    View All

    IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results

    Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in 2024.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the second quarter of 2025, which are increases of 18% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per share of common stock for the third quarter of 2025, payable on August 28, 2025. ORLANDO, Fla., Aug. 01, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ

    8/1/25 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

    ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI52cf21ec526142b8b6142d07c87cfcf9. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available re

    7/25/25 4:05:00 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

    Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

    5/5/25 7:00:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by iRadimed Corporation

    SC 13G/A - IRADIMED CORP (0001325618) (Subject)

    11/14/24 3:35:27 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

    SC 13G/A - IRADIMED CORP (0001325618) (Subject)

    2/13/24 4:25:25 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

    SC 13G/A - IRADIMED CORP (0001325618) (Subject)

    2/12/24 12:03:30 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care